Logo

American Heart Association

  97
  0


Final ID: 4120785

Differential Cardiovascular Impact of ω-3 Fatty Acid in Patients at High Cardiovascular Risk in Asians versus non-Asians: Sub-analysis of the STRENGTH Randomized Clinical Trial

Abstract Body (Do not enter title and authors here): Background: Racial differences in lipid and cardiovascular risk profiles are well-established including for Asians. The STRENGTH trial found that ω-3 carboxylic acid (CA) formulation of eicosapentaenoic acid and docosahexaenoic acid did not result in significant changes in cardiovascular event rates compared with corn oil in statin-treated patients at high cardiovascular risk, however drug efficacy may vary by race. We evaluated and compared the cardiovascular treatment effect of ω-3 CA between Asians and non-Asians in this sub-analysis of the STRENGTH trial.

Methods: The STRENGTH trial was a double-blinded 1:1 randomized controlled trial of 13,078 high cardiovascular risk patients enrolled during 10/30/2014-6/14/2017 at 675 centers. Efficacy of ω-3 CA for Asians (n=1,355) and non-Asians (n=11,723) and interactions between race and treatment effect were assessed. The primary endpoint is a composite of cardiovascular death, non-fatal myocardial infarction, stroke, coronary revascularization and unstable angina hospitalizations.

Results: Key differences in baseline characteristics include Asians having significantly higher prevalence of men, secondary prevention, and lower total cholesterol, LDL, apoB100, and hsCRP. In Asians, ω-3 CA was associated with significantly lower primary endpoint during follow-up, with 81/698 events [Kaplan-Meier (KM) Estimate: 14.8%] in the ω-3 CA group, 103/657 events (KM Estimate: 20.4%) in the corn oil group, and hazard ratio (HR) 0.72, 95% CI 0.54-0.96, P=0.026 (Figure A). In non-Asians, there was not a significant difference in primary endpoint rates between the two groups, with 704/5841 events (KM Estimate: 15.6%) in the ω-3 CA group, 692/5882 events (KM Estimate: 15.9%) in the corn oil group, and HR 1.03 95% CI 0.93-1.14, P=0.60 (Figure B). There were significant interactions between race (Asian versus non-Asian) and treatment group for the primary endpoint (P=0.021) and non-fatal stroke (P=0.016) and remained significant after adjusting for other covariates.

Conclusion: ω-3 CA was associated with significant reduction in major adverse cardiovascular events compared with corn oil in Asians but not in non-Asian patients with high cardiovascular risk. Further research is necessary to elucidate the mechanisms for potentially beneficial effects of ω-3 CA unique to Asian race.
  • Wang, Tom Kai Ming  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Nicholls, Stephen  ( Victorian Heart Hospital , Clayton , Victoria , Australia )
  • St John, Julie  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Wolski, Kathy  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Nissen, Steven  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Author Disclosures:
    Tom Kai Ming Wang: DO NOT have relevant financial relationships | Stephen Nicholls: DO have relevant financial relationships ; Researcher:AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx and Sanofi-Regeneron:Active (exists now) ; Consultant:Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Cyclarity, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, Novo Nordisk, CSL Seqirus and Vaxxinity:Active (exists now) | Julie St John: DO NOT have relevant financial relationships | Kathy Wolski: DO NOT have relevant financial relationships | Steven Nissen: DO have relevant financial relationships ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead Pharmaceuticals:Active (exists now) ; Research Funding (PI or named investigator):Bristol Myers Squibb:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Silence Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):New Amsterdam Phrma.:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Insights in Lipids and lipid lowering therapies

Monday, 11/18/2024 , 09:45AM - 11:00AM

Abstract Oral Session

More abstracts on this topic:
Analysis of Racial Disparities in the Training Path to Cardiology: Trends from 2012 to 2022

Gopal Jay, Rahafrooz Maryam, Chan Nathan, Gopal Devraj, Kepler Joshua, Ren Junling, Gopal Indulekha, Joseph Jacob

Acetylation of mitochondrial LCAD and SOD2 promotes metabolic dysfunction, oxidative stress, multi-organ damage and hypertension

Dikalov Sergey, Nogueira Marina, Polosukhin Vasiliy, Gius David, Milne Ginger, Dikalova Anna

More abstracts from these authors:
Advance-HTN Trial Participant Characteristics Associated with a Failure to be Randomized

Mendpara Vaidehi, St John Julie, Wolski Kathy, Sarraju Ashish, Rodman David, Nissen Steven, Laffin Luke

Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease

Bonaca Marc, Canonico Mario Enrico, Li Na, Sasiela William, Nissen Steven, Lincoff Abraham, Nicholls Stephen

You have to be authorized to contact abstract author. Please, Login
Not Available